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Abstract
Background: Adverse reactions associated to anti-thyroid drugs include fever, rash, arthralgia, agranulocytosis and
hepatitis that are thought to be hypersensitivity reactions. Five cases of pleural effusion associated to thionamides
have also been reported, two with propylthiouracil and three with carbimazole.
Case presentation: We report here a case of a 75-year-old man admitted because of unilateral pleural effusion.
The patient had a recent diagnosis of hyperthyroidism and 6 days after starting methimazole complained of
pleuritic chest pain. He had elevated C-reactive protein and erythrocyte sedimentation rate and normal white
blood cell count and liver enzymes. Chest radiography showed a moderate right pleural effusion and the ultrasound
revealed a loculated effusion that was shown to be an eosinophilic exudate.
Conclusions: The temporal relationship between methimazole intake and the development of pleural effusion combined
with the extensive exclusion of alternative causes, namely infectious, neoplastic and primary auto-immune diseases, led to
the diagnosis of hypersensitivity reaction to methimazole. The thionamide was stopped and corticosteroid was started with
complete resolution of the pleural effusion in 3 months.
Awareness of this rare adverse reaction of anti-thyroid drugs is important and methimazole can be added to the list of
possible etiologies of drug-induced eosinophilic pleural effusion.
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Background
Methimazole or thiamazole, together with carbimazole
and propylthiouracil, are anti-thyroid medications belonging
to the class of thionamides [1]. Methimazole is the active
metabolite of carbimazole and has similar pharmacological
activity. Thionamides side effects are rare and include fever,
rash, arthralgias, agranulocytosis and hepatitis [1]. Pleuro-
pulmonary complications of these drugs are even rarer.
The mechanisms of thionamides side effects are
poorly understood but are generally considered to be
dose independent by immunologic hypersensitivity. Anti-
neutrophil cytoplasmic antibody (ANCA)-positive vasculitis
associated to anti-thyroid drugs have been well described
[2–12]. Additionally, a drug-induced lupus-like syndrome
and hypersensitivity reactions with cutaneous, renal or
pulmonary involvement have also been identified [13–17].
Recently, five cases of pleural effusion induced by anti-
thyroid drugs, two with propylthiouracil and three with
carbimazole, have been reported in the literature [18–22].
We describe here a patient with hyperthyroidism who
developed an unilateral eosinophilic pleural effusion a
few days after the initiation of methimazole therapy. An
extensive diagnostic evaluation excluded infectious and
neoplastic diseases as well as primary auto-immune or
vasculitic disease as the cause of serositis. Pleural
effusion was thus considered as a manifestation of
methimazole-hypersensitivity reaction. To the best of
our knowledge, this is the first case of methimazole-
induced pleural effusion described in the literature.
Case presentation
A 75-year-old man was admitted with unilateral right
pleural effusion. He presented with pleuritic chest pain
that started 4 days before and had no other relevant
complaints, namely fever, diaphoresis, dyspnoea, cough,
haemoptysis, rash or arthralgia.
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He had a past medical history of arterial hypertension,
atrial fibrillation, end-stage renal disease on haemodialysis,
peripheral artery disease and prostatic hyperplasia. His
ambulatory prescription consisted of enalapril, carvedilol,
nifedipine, aspirin, warfarin, omeprazole and tansulosin,
for more than 3 years. Amiodarone had been suspended,
2 months before, due to ocular toxicity. There was no evi-
dence of thoracic trauma or previous asbestos exposure.
Ten days before hospital admission the patient had an
episode of unstable angina. He underwent coronary angiog-
raphy which showed a lesion in the circumflex artery and
angioplasty and implantation of an intracoronary stent
coated drug were performed. He started treatment with
clopidogrel. By this time blood tests showed low TSH
(0.055 uU/mL; reference range: 0.55–4.78 uU/mL) and high
FT4 (1.81 ng/dL; reference range: 0.80–1.76 ng/dL) and
FT3 (4.84 pg/mL; reference range: 2.3–4.2 pg/mL).
Methimazole was started. There was no evidence of pleural
effusion at that time.
At hospital admission the patient was afebrile, with a
respiratory rate of 18 cycles per minute and oxygen
saturation of 95% on room air. His blood pressure was
131/63 mmHg and heart rate was 76 beats per minute.
Cardio-pulmonary examination revealed arrhythmic
heart sounds, diminished breath sounds on the lower
half of the right lung and dullness on percussion at
that site was noted. All other findings on physical
examination were unremarkable.
Laboratory tests showed normal leucocytes (6 510/uL)
and eosinophils (320/uL) counts, elevated C-reactive
protein (10.9 mg/dL) and erythrocyte sedimentation rate
(58 mm) and normal liver enzymes; TSH (0.019 uU/mL)
was low and FT4 (2.51 ng/dL) and FT3 (7.22 pg/mL)
were high; INR (1.13) was not in therapeutic range.
Arterial blood gases, while the patient was in room air
and after haemodialysis, showed hypoxemia (PO2:
57.6 mmHg) and metabolic alkalosis (pH: 7.48, PCO2:
37.8 mmHg, HCO3
−: 28.9 mmol/L). Electrocardiogram
revealed atrial fibrillation rhythm without acute ischaemic
changes. Chest radiography showed a homogenous opacity
in the lower half of the right pulmonary field and chest
ultrasound findings were suggestive of pleural effusion with
septa. Right-sided diagnostic thoracentesis was performed.
The aspirated pleural fluid had 2277 cells/uL with 70%
being macrophages, 18% eosinophils and 12% neutrophils.
The effusion protein/serum protein ratio was 0.7 and the
effusion lactate dehydrogenase (LDH)/serum LDH ratio
was 1.8. Pleural fluid cultures revealed no bacteria or
mycobacteria and no malignant cells were detected on
cytological examination of pleural fluid. Bronchofibroscopy
did not reveal any macroscopic lesion. Bronchoalveolar
fluid cultures were negative and the cytological analysis of
the fluid showed no malignant cells. Pleural biopsy was not
performed due to high bleeding risk as the patient was on
double anti-platelet and anticoagulation therapy. The blood
cultures yielded no bacteria or mycobacteria and blood
interferon gamma release assay for Mycobacterium
tuberculosis was negative. Anti-nuclear antibodies (ANA),
anti-double stranded DNA (anti-dsDNA) antibodies and
ANCA were negative.
Thoracic, abdominal and pelvic computed tomography
(CT) was performed and confirmed the moderate right
pleural effusion with no other positive findings. Thoracic
CT angiography excluded pulmonary embolism. Although
Dressler syndrome was considered [23], it usually occurs
after myocardial infarction rather than unstable angina and
moreover, the short interval between the cardiac event and
the pleural effusion did not support this hypothesis [24].
Titers of thyroglobulin (Tg), anti-Tg, anti-thyroperoxidase
and anti-TSH receptor antibodies were normal. The cer-
vical ultrasonography revealed thyroid micronodules and
there was no radioisotope uptake in the 99mTechnetium
thyroid scintigraphy. Hyperthyroidism was interpreted as
type II amiodarone induced thyrotoxicosis.
After the exclusion of neoplastic, infectious and pri-
mary auto-immune diseases, considering an exudative
pleural effusion with significant eosinophilia and a
well-established temporal relation with the initiation
of methimazole treatment, a diagnosis of methimazole-
induced pleural effusion was made. A single organ drug
hypersensitivity reaction was assumed in the absence of
evidence of other organ involvement. Anti-thyroid medica-
tion was suspended, systemic corticosteroid was initiated
and all other medications were maintained. Progressive and
rapid clinical and laboratorial improvement was evident
with normalization of inflammatory biomarkers and thyroid
function and resolution of hypoxemia. Three months after
methimazole was suspended there was complete resolution
of pleural effusion.
Discussion
Thionamides-induced auto-immune phenomena, includ-
ing pleuro-pulmonary complications, exhibit usually the
features of ANCA-positive systemic vasculitis. Stankus et
al. published, in 1992, the first case of propylthiouracil-
induced hypersensitivity vasculitis and since then 61 cases
of vasculitis associated to anti-thyroid drugs have been
reported, most involving propylthiouracil [15, 25]. There
are only nine reported cases of carbimazole-induced
vasculitis and seven cases of vasculitis associated to methi-
mazole [2–9, 13, 14, 17, 25–29]. In addition, a lupus-like
syndrome can be induced by any of the thionamides
[8, 13, 14, 21, 30]. Clinical manifestations are similar
to systemic lupus erythematosus (SLE) and usually
patients have positive anti-nuclear, anti-dsDNA and
anti-histone antibodies [21].
Pleuro-pulmonary complications of thionamides are
very rare and include alveolar hemorrhage, interstitial
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pneumonia, pulmonary cavitations and pleural effusion
that are considered adverse auto-immune reactions
triggered by these drugs [6, 7, 9, 18–22, 31, 32]. Five
cases of anti-thyroid drug-induced pleural effusion, two
with propylthiouracil and three with carbimazole, have
been described in the literature [18–22]. The case reported
here represents the first case of methimazole-associated
pleural effusion. The temporal relationship between initi-
ation of the drug and the appearance of pleural effusion,
the resolution of the effusion after withdrawal of methima-
zole with administration of corticosteroid, in the absence of
other potential cause for pleuritis, is consistent with the
diagnosis of drug-induced pleural effusion. Our case differs
from the previous reports by the short time between the
initiation of the thionamide and the onset of pleural effu-
sion that was only 6 days.
Pleural fluid of the two patients with propylthiouracil
associated pleuritis was an eosinophilic exsudate, as in
the case reported here [18, 19]. Pleural biopsy was made
in one of these patients and showed chronic inflammation
of the pleura with prominent eosinophils and both patients
had negative auto-immune markers. None of the three
patients with carbimazole-induced pleuritis had an
eosinophilic exudate [20–22]. Two of these three re-
ported cases had pleural nonspecific inflammatory
infiltrates and negative auto-immunity, namely ANA
and ANCA. The third patient had positive ANA, anti-
dsDNA and anti-histone antibodies and pleuritis was
considered as a drug-induced SLE-like syndrome.
As stated before, the mechanisms involved in these
cases are most likely non-dose dependent, exactly like in
drug induced liver injury where lesions occur via im-
munologic hypersensitivity [33] by generation of toxic
metabolites [34] or alternatively metabolites that induce
an immunological reaction [34, 35]. The inflammatory
response with abundant eosinophils in the case reported
here suggests that this represents a T cell drug hypersen-
sitivity reaction with polarization to T helper 2 cells pro-
ducing interleukin 4 and interleukin 5 that are known to
induce eosinophil differentiation. Interestingly, a recent
report by Uematsu et al. [36], identified a T helper 2 biased
lymphocyte response in a model of methimazole acute
liver injury mediated by microRNAs [36]. Another area of
increasing interest is that of risk factors for methimazole
adverse reactions. Thus, HLA-B*27:05 and other single
nucleotide polymorphisms were identified as possible risk
factors for anti-thyroid agranulocytosis [37], and the
prospect that certain microRNAs with effects on lung
development might represent prognostic tools in thyroid-
dependent lung disease [38] has also been recently
discussed.
The clinical and radiological evolution of this case was
identical to the cases of pleural effusion induced by other
thionamides. The anti-thyroid drug considered to be
associated to the effusion was withdrawn in all patients
and alternative anti-thyroid therapy options were initiated
in three of the five patients [19, 20, 22]. The cessation of
the drug was followed by resolution of the effusion within
3 to 5 months. Two of the five patients were given corti-
coesteroid for a short period of time and in decreasing
dosages and in these cases a more rapid resolution of
serositis was observed [19, 21]. In the present case, a diag-
nosis of type II hyperthyroidism, due to cytotoxic effect of
amiodarone on thyroid cells, was made and thus mainten-
ance of thionamides treatment was not required.
Conclusions
In conclusion, we describe here the first case of eosino-
philic pleuritis associated to methimazole due to an
hypersensitivity immune drug reaction with full remis-
sion after withdrawal the drug. Awareness of clinicians
about the possibility of this drug adverse reaction may
help identification of future similar cases.
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